Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer

Cancer Treatment Reviews

Volumn 35, Issue 2, 2009, Pages 167-174

  El Maalouf, Ghassan ^a   Le Tourneau, Christophe ^a   Batty, Georges Nicolas ^b   Faivre, Sandrine ^a   Raymond, Eric ^a  

^a BEAUJON HOSPITAL   (France)

^b ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Antimetabolites; EGFR; Pancreatic cancer; Platinum agents; Predictive markers; Prognosis markers; Resistance; Tyrosine kinases inhibitors

Indexed keywords

AXITINIB; BEVACIZUMAB; CETUXIMAB; ERLOTINIB; FC RECEPTOR IIA; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; THYMIDYLATE SYNTHASE; THYMOQUINONE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

APOPTOSIS; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DNA REPAIR; DNA SYNTHESIS INHIBITION; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; DRUG UPTAKE; GENE MUTATION; GENE TARGETING; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; PANCREAS CANCER; PARACRINE SIGNALING; PROGNOSIS; REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 61449119672     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.10.002     Document Type: Review

References (91)

1. Cress R.D., Yin D., Clarke L., et al. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control 17 (2006) 403-409
2. Burris III H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997) 2403-2413
3. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007) 1960-1966
4. Philip P.A. Targeting angiogenesis in pancreatic cancer. Lancet (2008)
5. Bergman A.M., Pinedo H.M., and Peters G.J. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5 (2002) 19-33
6. Garcia-Manteiga J., Molina-Arcas M., Casado F.J., et al. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 9 (2003) 5000-5008
7. Goan Y.G., Zhou B., Hu E., et al. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59 (1999) 4204-4207
8. Nakano Y., Tanno S., Koizumi K., et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 96 (2007) 457-463
9. Javle M., Okazaki T., Evans D., et al. Polymorphisms of genes involved in gemcitabine metabolism correlate with prognosis in patients receiving neoadjuvant therapy for pancreatic cancer. J Clin Oncol (2008) 26 [May 20 Suppl. abstr 4501]
10. Yokoi K., and Fidler I.J. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res 10 (2004) 2299-2306
11. Graber H.U., Friess H., Zimmermann A., et al. Bak expression and cell death occur in peritumorous tissue but not in pancreatic cancer cells. J Gastrointest Surg 3 (1999) 74-80 [discussion 81]
12. Fahy B.N., Schlieman M.G., Virudachalam S., et al. Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 198 (2004) 591-599
13. Galmarini C.M., Clarke M.L., Falette N., et al. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 97 (2002) 439-445
14. Marsh S., McKay J.A., Cassidy J., et al. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 19 (2001) 383-386
15. Formentini A., Sander S., Denzer S., et al. Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker?. Int J Colorectal Dis 22 (2007) 49-55
16. Hu Y.C., Komorowski R.A., Graewin S., et al. Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer. Clin Cancer Res 9 (2003) 4165-4171
17. Takamura M., Nio Y., Yamasawa K., et al. Implication of thymidylate synthase in the outcome of patients with invasive ductal carcinoma of the pancreas and efficacy of adjuvant chemotherapy using 5-fluorouracil or its derivatives. Anticancer Drugs 13 (2002) 75-85
18. Ohrling K., Edler D., Hallstrom M., et al. Detection of thymidylate synthase expression in lymph node metastases of colorectal cancer can improve the prognostic information. J Clin Oncol 23 (2005) 5628-5634
19. Minari Y., Nio Y., Hirahara N., et al. Heterogeneic distribution of thymidine phosphorylase between primary tumors and metastatic lesions of human pancreatic ductal carcinoma: implications for the efficacy of chemotherapy with 5-FU or its derivatives. Cancer Chemother Pharmacol 47 (2001) 415-422
20. Salonga D., Danenberg K.D., Johnson M., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6 (2000) 1322-1327
21. Takao S., Takebayashi Y., Che X., et al. Expression of thymidine phosphorylase is associated with a poor prognosis in patients with ductal adenocarcinoma of the pancreas. Clin Cancer Res 4 (1998) 1619-1624
22. Nita M.E., Tominaga O., Nagawa H., et al. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer. Hepatogastroenterology 45 (1998) 2117-2122
23. Nakayama S., Takeda S., Kawase Y., et al. Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer. Ann Surg 240 (2004) 840-844
24. Rabik C.A., and Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33 (2007) 9-23
25. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24 (1998) 331-344
26. Dabholkar M., Bostick-Bruton F., Weber C., et al. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84 (1992) 1512-1517
27. Park D.J., Zhang W., Stoehlmacher J., et al. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 1 (2003) 162-166
28. Viguier J., Boige V., Miquel C., et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11 (2005) 6212-6217
29. Shirota Y., Stoehlmacher J., Brabender J., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19 (2001) 4298-4304
30. Kamikozuru H.K.H., Hayashi K., et al. ERCC1 Codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. J Clin Oncol, Asco Ann Meeting Proc Part I 25 18S (2007) 15012
31. Park D.J., Stoehlmacher J., Zhang W., et al. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61 (2001) 8654-8658
32. Stoehlmacher J., Ghaderi V., Iobal S., et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 21 (2001) 3075-3079
33. Fink D., Nebel S., Aebi S., et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56 (1996) 4881-4886
34. Vaisman A., Varchenko M., Umar A., et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58 (1998) 3579-3585
35. Kelland L.R., Mistry P., Abel G., et al. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res 52 (1992) 1710-1716
36. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7 (2007) 573-584
37. Vaisman A., Masutani C., Hanaoka F., et al. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. Biochemistry 39 (2000) 4575-4580
38. Kaseb A., Banerjee S., Wang Z., et al. Enhanced chemosensitivity to gemcitabine and oxaliplatin by thymoquinone in pancreatic cancer. J Clin Oncol 26 (2008) [May 20 Suppl. abstr 15565]
39. Thybusch-Bernhardt A., Beckmann S., and Juhl H. Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage. Int J Surg Invest 2 (2001) 393-400
40. Lemoine N.R., Hughes C.M., Barton C.M., et al. The epidermal growth factor receptor in human pancreatic cancer. J Pathol 166 (1992) 7-12
41. Saad E.D., and Hoff P.M. Molecular-targeted agents in pancreatic cancer. Cancer Control 11 (2004) 32-38
42. Xiong H.Q., and Abbruzzese J.L. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 29 (2002) 31-37
43. Ischenko I., Guba M., Yezhelyev M., et al. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis 10 (2007) 167-182
44. Yamanaka Y., Friess H., Kobrin M.S., et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13 (1993) 565-569
45. Uegaki K., Nio Y., Inoue Y., et al. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res 17 (1997) 3841-3847
46. Philip P.B.J., Fenoglio-Preiser C., et al. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study. J Clin Oncol ASCO Ann Meeting Proc Part I 25 18S (2007) LBA4509
47. Talar-Wojnarowska R., and Malecka-Panas E. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med Sci Monit 12 (2006) RA186-RA193
48. Bondar V.M., Sweeney-Gotsch B., Andreeff M., et al. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1 (2002) 989-997
49. Herbst R.S., Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5892-5899
50. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
51. Wacker B., Nagrani T., Weinberg J., et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13 (2007) 3913-3921
52. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
53. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004) 1201-1208
54. Chung K.Y., Shia J., Kemeny N.E., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23 (2005) 1803-1810
55. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
56. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
57. Kwak E.L., Jankowski J., Thayer S.P., et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12 (2006) 4283-4287
58. Immervoll H., Hoem D., Kugarajh K., et al. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch 448 (2006) 788-796
59. Kulke M.H., Blaszkowsky L.S., Ryan D.P., et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25 (2007) 4787-4792
60. Tzeng C.W., Frolov A., Frolova N., et al. Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Ann Surg Oncol 14 (2007) 2150-2158
61. Mendelsohn J., and Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 19 (2000) 6550-6565
62. Bibeau F., Crapez E., Di Fiore F., et al. Association of FcγRIIa and FcγRIIa polymorphisms with clinical outcome in metastatic colorectal cancer patients (mCRC) treated with cetuximab and irinotecan. J Clin Oncol 26 (2008) [May 20 Suppl. abstr 11004]
63. Buck E., Eyzaguirre A., Haley J.D., et al. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther 5 (2006) 2051-2059
64. Pao W., Wang T.Y., Riely G.J., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2 (2005) e17
65. Lievre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 (2006) 3992-3995
66. Dergham S.T., Dugan M.C., Kucway R., et al. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int J Pancreatol 21 (1997) 127-143
67. Le X., Shi Q., Wang B., et al. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res 20 (2000) 935-946
68. Riese II D.J., Komurasaki T., Plowman G.D., et al. Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2. J Biol Chem 273 (1998) 11288-11294
69. Xie K., Wei D., and Huang S. Transcriptional anti-angiogenesis therapy of human pancreatic cancer. Cytokine Growth Factor Rev 17 (2006) 147-156
70. Murphy L.O., Abdel-Wahab Y.H., Wang Q.J., et al. Receptors and ligands for autocrine growth pathways are up-regulated when pancreatic cancer cells are adapted to serum-free culture. Pancreas 22 (2001) 293-298
71. Pino M.S., Shrader M., Baker C.H., et al. Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. Cancer Res 66 (2006) 3802-3812
72. Jimeno A., Rubio-Viqueira B., Amador M.L., et al. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 65 (2005) 3003-3010
73. Chakravarti A., Loeffler J.S., and Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62 (2002) 200-207
74. Li J., Kleeff J., Giese N., et al. Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int J Oncol 25 (2004) 203-210
75. Jones H.E., Goddard L., Gee J.M., et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocrinol Relat Cancer 11 (2004) 793-814
76. Zhao S., Venkatasubbarao K., Lazor J.W., et al. Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res 68 (2008) 4221-4228
77. Yang J., Mani S.A., Donaher J.L., et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117 (2004) 927-939
78. Wang F., Sloss C., Zhang X., et al. Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells. Cancer Res 67 (2007) 8486-8493
79. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 (2004) 581-611
80. Weidner N., Semple J.P., Welch W.R., et al. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324 (1991) 1-8
81. Kuwahara K., Sasaki T., Kuwada Y., et al. Expressions of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. Pancreas 26 (2003) 344-349
82. Seo Y., Baba H., Fukuda T., et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88 (2000) 2239-2245
83. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7 (2001) 987-989
84. Kindler H.N.D., Hollis D., et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: a preliminary analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol, ASCO Ann Meeting Proc Part I 25 18S (2007) 4508
85. Kindler H.L., Friberg G., Singh D.A., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23 (2005) 8033-8040
86. Spano J.P., Chodkiewicz C., Maurel J., et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet (2008)
87. Jubb A.M., Hurwitz H.I., Bai W., et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24 (2006) 217-227
88. Deprimo S.E., Bello C.L., Smeraglia J., et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5 (2007) 32
89. Mahadevan D., and Von Hoff D.D. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 6 (2007) 1186-1197
90. Araujo R.P., Liotta L.A., and Petricoin E.F. Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discovery (2007)
91. Lau J.P., Weatherdon K.L., Skalski V., et al. Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides. Br J Cancer 91 (2004) 1166-1173